ESTRO37_ProgrammeBook

INTERDISCIPLINARY RADIOBIOLOGY CLINICAL BRACHYTHERAPY PHYSICS RTT YOUNG

MONDAY 23 APRIL 2018

15:20 > Clinical trials

Speaker: J. Alsner (Denmark)

 SP-0550

DEBATE This house believes that treatment intensification in stage III is a dream rather than a reality? 14:30 - 15:45  |  ROOM AUDITORIUM The basic assumption of dose intensification as a way to improve local tumor control and survival is that there is a clear dose-effect relation between dose, time and outcome, with higher doses leading to better tumor control. The favorable results of stereotactic radiotherapy support this paradigm, while randomized studies such as RTOG0617 seem to defeat it. In this session, we will discuss the pros and cons of dose escalation in stage III NSCLC as well as toxicity of OARs, competing events and the integration with systemic therapy and in which direction we should move in the future.

Chair: D. De Ruysscher (The Netherlands) Co-Chair: E. Rivin del Campo (France)

14:30 > For the motion

Speaker: C. Faivre-Finn (United Kingdom)

  SP-0551

14:50 > Against the motion: Treatment intensification in stage III NSCLC is a dream rather than a reality? Speaker: J. Belderbos (The Netherlands)

 SP-0552

15:10 > For the motion rebuttal

Speaker: C. Faivre-Finn (United Kingdom)

15:20 > Against the motion rebuttal

Speaker: J. Belderbos (The Netherlands)

15:30 > Discussion

Programme and Exhibition Guide | SCIENTIFIC PROGRAMME

159